Emmanuel Eni Amadi
Dr. Emmanuel Eni Amadi obtained his PhD in Biomedical Sciences in the areas of Genotoxicology and Nanotoxicology of nanoparticles used in the nanomedicines for the treatment of chronic pulmonary diseases (asthma, COPD, and lung cancer) under Professor Diana Anderson at the Faculty of Life Sciences, University of Bradford, UK.
His research focuses on the assessment of the genetic toxicology and nanotoxicology of 2D graphene oxide nanomaterials used in nanomedicine for asthma, COPD, and lung cancer – mainly on the molecular mechanisms in response to DNA Damage, protein/gene expression, and cell-cycle signalling pathways involved in nanoparticles-induced pathogenesis of lung cancer, asthma, and COPD with the prospect of identifying early biomarkers and translational therapeutic targets.
He also holds a B.Pharm, MSc, PGDip. Pharm, and Executive MBA with specialty in business strategy. He was a Pharmacy Manager for a number of Pharmacy Companies in the UK and overseas. Most recently, he was the Founder/CEO and Superintendent Pharmacist Director of a Pharmacy Company in Manchester, and a contractor to the UK National Health Service (NHS) (2011-2018). Currently, he sits on the Board as a Trustee/ Non-Executive Company Director of THE OAK LEARNING PARTNERSHIP – a Multi-Academy Trust in Bury, Greater Manchester, UK, where he provides oversight and strategic leadership to the Executive Headteachers with a budgetary control of £10 Million pounds per annum. He was an Associate member of the Institute of Directors (IoD), North West region, Manchester. In 2017, he was elected a Fellow of the Chartered Management Institute (FCMI) due to his outstanding contribution to business leadership and management. He is a registered pharmacist with the General Pharmaceutical Council (GPhC), and a Founding Member of the Royal Pharmaceutical Society, London.